|

Peptide vaccine Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Indications

  • ALK Fusion Protein Expression1
  • NSCLC Stage IV1
  • Lung Cancer1
  • Cancer1

Baltimore, Maryland1 trial

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Johns Hopkins University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.